Goldin, Jonathan

Cyclophosphamide versus placebo in scleroderma lung disease

Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine

Systemic Sclerosis and Related DiseasesInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Cited by 1,677

Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper

Lynch, D. A., Sverzellati, N., Travis, W. D., Brown, K. K., Colby, T. V., Galvin, J. R., Goldin, J. G., Hansell, D. M., Inoue, Y., Johkoh, T., et al. (2018) · The Lancet Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseases

Cited by 1,030

Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial

Richeldi, L., Fernández Pérez, E. R., Costabel, U., Albera, C., Lederer, D. J., Flaherty, K. R., Ettinger, N., Perez, R., Scholand, M. B., Goldin, J., et al. (2020) · The Lancet Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisConnective Tissue Growth Factor Research

Cited by 293

Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial

Lancaster, L., Cottin, V., Ramaswamy, M., Wuyts, W. A., Jenkins, R. G., Scholand, M. B., Kreuter, M., Valenzuela, C., Ryerson, C. J., Goldin, J., et al. (2024) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 80

Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease

Martyanov, V., Kim, G.-H. J., Hayes, W., Du, S., Ganguly, B. J., Sy, O., Lee, S. K., Bogatkevich, G. S., Schieven, G. L., Schiopu, E., et al. (2017) · PLOS ONE

Systemic Sclerosis and Related DiseasesInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Cited by 71

Translating AI to Clinical Practice: Overcoming Data Shift with Explainability

Choi, Y., Yu, W., Nagarajan, M. B., Teng, P., Goldin, J. G., Raman, S. S., Enzmann, D. R., Kim, G. H. J., & Brown, M. S. (2023) · RadioGraphics

Explainable Artificial Intelligence (XAI)Artificial Intelligence in Healthcare and Education

Cited by 65

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)

Corte, T. J., Lancaster, L., Swigris, J. J., Maher, T. M., Goldin, J. G., Palmer, S. M., Suda, T., Ogura, T., Minnich, A., Zhan, X., et al. (2021) · BMJ Open Respiratory Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related Diseases

Cited by 59

Late Breaking Abstract - Safety, tolerability and antifibrotic activity of bexotegrast: Phase 2a INTEGRIS-IPF study (NCT04396756)

Wuyts, W. A., Valenzuela, C., Jenkins, G., Goldin, J. G., Kim, G. H. J., Jurek, M., Turner, S., Decaris, M., Barnes, C. N., Lefebvre, É., et al. (2023) · Idiopathic interstitial pneumonias

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 7

Improved quality of life, reduced quantitative lung fibrosis in a trial of inhaled pirfenidone for idiopathic pulmonary fibrosis

Kim, G. H. J., Woodhead, F. A., Nair, D., Bao, H., Lazarus, H. M., Conoscenti, C. S., & Goldin, J. G. (2026) · BMC Pulmonary Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 1